Benitec Biopharma (BNTC) vs Prelude Therapeutics (PRLD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed Benitec Biopharma (BNTC) over the past year, gaining 166.0% versus a loss of 34.8%. Over five years, PRLD leads with a -76.4% price change compared with -85.3% for BNTC. Prelude Therapeutics is the larger company by market cap ($312.0 million vs $307.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTC | PRLD |
|---|---|---|
| Share price | $8.80 | $3.91 |
| Market cap | $306.97M | $312.03M |
| 1-day change | -2.11% | +2.09% |
| YTD return | -33.26% | +32.07% |
| 1-year return | -34.76% | +165.97% |
| 5-year return | -85.27% | -76.45% |
| EPS (TTM) | $-0.98 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.76 | $6.83 |
| 52-week low | $8.52 | $1.15 |
| Distance from 52-week high | -47.49% | -42.75% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +176.48% | +135.29% |
| Average volume | 152.08K | 477.45K |
| Shares outstanding | 34.88M | 65.08M |
| Employees | 24 | 79 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed BNTC by 200.7 percentage points over the past year.
About Benitec Biopharma
BNTC stock →Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
BNTC vs PRLD FAQ
Which is bigger, Benitec Biopharma or Prelude Therapeutics?
Prelude Therapeutics (PRLD) is larger, with a market capitalization of $312.03M compared with $306.97M for Benitec Biopharma (BNTC).
Which stock has performed better over the past year, BNTC or PRLD?
PRLD returned +165.97% over the past 12 months, compared with -34.76% for BNTC (price return, excluding dividends). Past performance does not predict future results.
Are Benitec Biopharma and Prelude Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.